Treatment Options for Chronic CSCR

Key Takeaways

• Chronic central serous chorioretinopathy (CSCR) requires active management to prevent long-term vision impairment and retinal damage.
• Central serous chorioretinopathy treatment includes photodynamic therapy, laser-based approaches, medications, and lifestyle modification depending on severity and duration.
• Early intervention with appropriate central serous chorioretinopathy treatment significantly improves visual outcomes and reduces recurrence.
• Addressing underlying triggers such as stress and corticosteroid use is a critical part of long-term management.

Chronic central serous chorioretinopathy (CSCR) is a retinal disorder characterized by persistent or recurrent fluid accumulation beneath the macula, leading to prolonged visual disturbances. Unlike acute CSCR, which often resolves spontaneously, chronic CSCR can last for several months or recur repeatedly, increasing the risk of permanent retinal damage [1].

Central serous chorioretinopathy treatment for chronic cases typically includes photodynamic therapy, laser-based treatments, medications, and lifestyle interventions aimed at reducing fluid leakage and preserving vision. Understanding the full range of treatment options allows patients to make informed decisions and actively participate in their care.

What Is Chronic CSCR?

CSCR occurs when fluid leaks from the choroidal circulation into the subretinal space, causing a localized detachment of the retina. In chronic cases, this fluid persists beyond three to six months or recurs frequently, leading to structural and functional damage [2]. Over time, chronic fluid accumulation can affect the retinal pigment epithelium (RPE) and photoreceptors, resulting in:

• Persistent blurred or dim vision
• Metamorphopsia (distorted or wavy vision)
• Reduced contrast sensitivity
• Difficulty reading or recognizing faces

Because of these risks, timely and appropriate central serous chorioretinopathy treatment is essential to prevent irreversible vision loss.

Causes and Risk Factors

Although the exact cause of CSCR remains unclear, several risk factors are strongly associated with its development and persistence [3]. These include:

• Chronic psychological stress leading to elevated cortisol levels
• Use of corticosteroids (oral, inhaled, topical, or injected)
• Hypertension and cardiovascular disease
• Sleep disorders such as obstructive sleep apnea
• Male gender and middle age
• High-pressure or “type A” personality traits

Addressing these underlying factors is an integral part of central serous chorioretinopathy treatment, as they contribute to both onset and recurrence.

When Is Treatment Necessary?

Not all cases of CSCR require immediate intervention. Acute cases are often monitored, as spontaneous resolution can occur within a few months. However, chronic CSCR typically requires active treatment. Intervention is recommended when:

• Subretinal fluid persists beyond 3–6 months
• Vision continues to deteriorate
• Recurrences occur frequently
• Both eyes are affected
• Occupational or lifestyle demands require stable vision

At this stage, initiating central serous chorioretinopathy treatment is crucial to protect visual function and prevent long-term damage.

Treatment Options for Chronic CSCR

1. Photodynamic Therapy (PDT)

Photodynamic therapy is widely regarded as the most effective treatment for chronic CSCR. It involves intravenous administration of a light-sensitive drug (verteporfin), followed by activation with a low-energy laser directed at the affected area [4]. This treatment works by:

• Reducing abnormal choroidal vascular permeability
• Decreasing fluid leakage
• Promoting reabsorption of subretinal fluid

PDT is often considered the first-line central serous chorioretinopathy treatment for chronic or persistent cases due to its high success rate and favorable safety profile.

2. Laser Photocoagulation

Laser photocoagulation is used to directly seal leaking points in the retina. It is most effective when leakage occurs away from the central macula. Advantages include:

• Faster resolution of fluid accumulation
• Reduced recurrence in selected cases

However, because it can cause retinal scarring, this method is used selectively in central serous chorioretinopathy treatment, particularly when lesions are located outside critical visual areas.

3. Subthreshold (Micropulse) Laser Therapy

Subthreshold laser therapy delivers low-energy pulses that stimulate cellular repair without causing visible retinal damage [5]. Benefits of this approach include:

• Minimal risk of scarring
• Preservation of retinal structure
• Suitability for treatment near the macula

This technique is increasingly used as a safer alternative and is becoming an important component of modern central serous chorioretinopathy treatment strategies.

4. Medical Therapy

Medications may be used in certain cases, especially when laser or photodynamic therapy is not feasible. Common pharmacologic options include:

• Mineralocorticoid receptor antagonists (e.g., eplerenone, spironolactone), which reduce choroidal vascular permeability [6]
• Anti-VEGF agents, though less commonly used, may be beneficial in select patients

Medical therapy serves as an adjunct to other forms of central serous chorioretinopathy treatment, particularly in patients with systemic risk factors.

5. Lifestyle and Risk Factor Modification

Lifestyle changes are a fundamental and often underestimated aspect of central serous chorioretinopathy treatment. Recommended strategies include:

• Stress reduction through mindfulness, therapy, or relaxation techniques
• Regular physical activity
• Adequate sleep and proper sleep hygiene
• Avoidance or reduction of corticosteroid use (if medically appropriate)
• Blood pressure management

These measures not only support recovery but also reduce the likelihood of recurrence.

Treatment Comparison

Monitoring and Follow-Up

Ongoing monitoring is essential to evaluate the effectiveness of central serous chorioretinopathy treatment and detect recurrence early. Patients are typically followed using:

• Optical coherence tomography (OCT) to assess fluid levels
• Visual acuity testing
• Fundus examination

Follow-up intervals depend on disease severity and treatment type but are generally more frequent during active disease.

Prognosis and Long-Term Outlook

The prognosis for chronic CSCR varies depending on how early treatment is initiated and how well the condition responds to therapy. With timely and appropriate central serous chorioretinopathy treatment, many patients experience significant improvement in vision. However, delayed or untreated cases may result in:

• Permanent damage to the retinal pigment epithelium
• Persistent visual distortion
• Reduced central visual acuity

Adherence to treatment and follow-up recommendations is critical for achieving optimal outcomes.

When to Seek Medical Attention

Patients should seek immediate evaluation if they notice:

• Sudden worsening of vision
• Distorted or wavy lines
• Persistent blurred central vision
• Difficulty reading or focusing

Prompt diagnosis allows early initiation of central serous chorioretinopathy treatment, reducing the risk of complications.

Conclusion

Chronic CSCR is a potentially vision-threatening condition that requires a proactive and comprehensive approach to management. A range of effective options—including photodynamic therapy, laser treatments, medications, and lifestyle changes—are available to address this condition.

By understanding the available therapies and working closely with an eye care specialist, patients can optimize their central serous chorioretinopathy treatment and protect their long-term vision. Early intervention, consistent monitoring, and addressing underlying risk factors remain the foundation of successful management.

References

1. Daruich, A., Matet, A., Dirani, A., Bousquet, E., Zhao, M., Farman, N., Jaisser, F., & Behar-Cohen, F. (2015). Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Progress in Retinal and Eye Research, 48, 82–118. https://doi.org/10.1016/j.preteyeres.2015.05.003
2. Nicholson, B., & Noble, J. (2016). Central serous chorioretinopathy: Update on pathophysiology and treatment. Survey of Ophthalmology, 61(5), 543–558. https://doi.org/10.1016/j.survophthal.2016.03.001
3. Mayo Clinic. (n.d.). Central serous chorioretinopathy. https://www.mayoclinic.org/diseases-conditions/central-serous-retinopathy/symptoms-causes/syc-20371043
4. van Rijssen, T. J., van Dijk, E. H. C., Yzer, S., Ohno-Matsui, K., Keunen, J. E. E., Schlingemann, R. O., & Boon, C. J. F. (2019). Central serous chorioretinopathy: Towards an evidence-based treatment guideline. Progress in Retinal and Eye Research, 73, 100770. https://doi.org/10.1016/j.preteyeres.2019.07.003
5. Scholz, P., Ersoy, L., Boon, C. J. F., Fauser, S., & Sadda, S. R. (2015). Subthreshold micropulse laser (577 nm) treatment in chronic central serous chorioretinopathy. Ophthalmologica, 234(4), 189–194. https://doi.org/10.1159/000439323
6. Bousquet, E., Beydoun, T., Rothschild, P. R., Bergin, C., Zhao, M., Batista, R., Brandely, M. L., Couraud, B., Farman, N., Gaudric, A., & Behar-Cohen, F. (2015). Spironolactone for nonresolving central serous chorioretinopathy: A randomized controlled crossover study. Retina, 35(12), 2505–2515. https://pmc.ncbi.nlm.nih.gov/articles/PMC4697359/